ENDRA Life Sciences Inc. (NASDAQ: NDRA, "ENDRA" or "the Company"), a pioneer in imaging technology focused on the early detection and monitoring of metabolic dysfunction-associated liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), announced today that it has received commitments totaling $4.90 million in private placements (the Offering) from top institutional and cryptocurrency investors.
The proceeds raised will be used to launch the Digital Asset Reserve ("DAT") strategy, which will be led by Arca Investment Management, LLC ("Arca"), focusing on its most trusted assets in the decentralized finance (DeFi) space, initially investing in tokens of leading decentralized exchanges and protocols, with a focus on perpetual contract assets such as HYPE.
Pursuant to the Securities Purchase Agreement, the Investor agrees to purchase 744,340 Common Shares (or the corresponding Advance Option Certificate) and warrants in which up to 1,488,680 Common Shares may be purchased. The Warrants are available for immediate call-over at a call-over price of $6.32 per share, valid for a five-year period. The Composite Offering Price per Common Share (or Advance Option Certificate) and its accompanying Warrants is $6.57. The Advance Option Certificate has a call-over price of $0.0001 per share, which is available for immediate call-over and continues to be valid until the call-over.
ENDRA Life Sciences Announces Market Targeted Private Offering of Up to $14.40 million to Launch Digital Asset Treasury Strategy Managed by Arca
2025-10-14 00:56:27
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
